---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-217481"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2023-08-22T23:59:59+00:00"
generated_at: "2026-06-11T05:39:21.598947+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio and WuXi ATU expand GMP manufacturing for CABA-201; dedicated suite for commercial readiness

## Summary
- WuXi ATU to provide GMP manufacturing for CABA-201, including commercial readiness, under expanded work orders.
- Dedicated suite added for CABA-201 and MuSK-CAART programs; initial 18-month term with two 18-month extensions at Cabaletta's option.
- Termination fee revised to $1.08M if both programs terminated; Cabaletta can terminate with 6 months' notice.
- Expansion supports planned parallel Phase 1/2 trials in SLE and myositis, plus potential late-stage trials.
- Cabaletta cites capital-efficient manufacturing strategy and prior successful collaboration with WuXi ATU.

## SEC filing metadata
- accession: 0001193125-23-217481
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2023-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312523217481/0001193125-23-217481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312523217481/d524786d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-217481
- JSON: https://secwatch.observer/filing/0001193125-23-217481.json
- Plain text: https://secwatch.observer/filing/0001193125-23-217481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.